LCM
VRTX icon

Logan Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Logan Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2
Closed -$783 – 470
2025
Q3 		$783 Hold
2
– – ﹤0.01% 440
2025
Q2 		$890 Hold
2
– – ﹤0.01% 433
2025
Q1 		$970 Hold
2
– – ﹤0.01% 516
2024
Q4 		$805 Buy
+2
New +$927 ﹤0.01% 493

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Logan Capital Management's VRTX Position: Q4 2025 in Review

Logan Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2025, closing a stake of 2 shares — an estimated $783 sold.

Logan Capital Management first reported a position in VRTX in Q4 2024 and held it in 4 quarters. The position peaked at $970 in Q1 2025. 1,668 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

  • Logan Capital Management reported no remaining Vertex Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Logan Capital Management sold 2 Vertex Pharmaceuticals shares in Q4 2025, an estimated $783.
  • Logan Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2024 and held it in 4 quarters.
  • Logan Capital Management's Vertex Pharmaceuticals position peaked at $970 in Q1 2025.
  • 1,668 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on Logan Capital Management's 13F filing for Q4 2025, filed 12 Feb 2026.